- Home
- NEGG vs AMRN Comparison
NEGG vs AMRN Comparison
Compare NEGG & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEGG
- AMRN
- Stock Information
- Founded
- NEGG 2001
- AMRN 1989
- Country
- NEGG United States
- AMRN Ireland
- Employees
- NEGG N/A
- AMRN N/A
- Industry
- NEGG Other Specialty Stores
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- NEGG Consumer Discretionary
- AMRN Health Care
- Exchange
- NEGG Nasdaq
- AMRN Nasdaq
- Market Cap
- NEGG 122.3M
- AMRN 216.0M
- IPO Year
- NEGG 2010
- AMRN 1993
- Fundamental
- Price
- NEGG $49.24
- AMRN $16.90
- Analyst Decision
- NEGG
- AMRN Strong Sell
- Analyst Count
- NEGG 0
- AMRN 1
- Target Price
- NEGG N/A
- AMRN $12.00
- AVG Volume (30 Days)
- NEGG 648.5K
- AMRN 174.2K
- Earning Date
- NEGG 08-28-2025
- AMRN 07-30-2025
- Dividend Yield
- NEGG N/A
- AMRN N/A
- EPS Growth
- NEGG N/A
- AMRN N/A
- EPS
- NEGG N/A
- AMRN N/A
- Revenue
- NEGG $1,235,576,000.00
- AMRN $214,112,000.00
- Revenue This Year
- NEGG N/A
- AMRN N/A
- Revenue Next Year
- NEGG N/A
- AMRN N/A
- P/E Ratio
- NEGG N/A
- AMRN N/A
- Revenue Growth
- NEGG N/A
- AMRN N/A
- 52 Week Low
- NEGG $3.32
- AMRN $7.08
- 52 Week High
- NEGG $56.00
- AMRN $17.49
- Technical
- Relative Strength Index (RSI)
- NEGG 91.69
- AMRN 71.53
- Support Level
- NEGG $15.31
- AMRN $16.12
- Resistance Level
- NEGG $17.52
- AMRN $17.49
- Average True Range (ATR)
- NEGG 4.56
- AMRN 0.96
- MACD
- NEGG 2.70
- AMRN 0.05
- Stochastic Oscillator
- NEGG 85.35
- AMRN 90.37
About NEGG Newegg Commerce Inc.
Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home, and gaming products and provides certain third-party logistics services globally. Geographically, it operates in United States, Canada, and Rest of World.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.